相关实验视频

Updated: Jan 7, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

一种对酶有反应的伊米基莫德原药,用于在瘤微环境中的精确免疫激活

Elsa Cannoni¹, Israa Al Jamal¹, Rony Eid¹

¹University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer, 4 rue Michel-Brunet, TSA 51106, 86073 Poitiers cedex 9, France.

Bioconjugate chemistry

|December 31, 2025

概括

研究人员开发了一种针对伊米基莫德 (IMQ) 的新型前药,可在瘤内选择性释放免疫调节器. 这种有针对性的方法通过最小化全身毒性和最大化抗瘤免疫反应来增强癌症免疫疗法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药物运输药物运输药物运输

背景情况:

小分子免疫调节剂,如伊米基莫德 (IMQ) 是癌症免疫治疗中生物药物的替代品.
目前IMQ的使用仅限于局部应用,因为由于广泛的托尔类受体 (TLR) 表达引起的全身毒性风险.

研究的目的:

开发一种用于瘤微环境内选择性输送IMQ的前药物.
克服系统性IMQ的局限性,并将其应用扩展到各种固体瘤.

主要方法:

设计了一种对β-glucuronidase有反应的,与白蛋白结合的前药物,以掩盖IMQ的免疫性.
向免疫能力较强的小鼠注射前药物,以评估系统性副作用和瘤特异性药物释放.
评估了前药对免疫细胞两极分化和瘤微环境中的抗体水平的影响.

主要成果:

这种前药可以在不引起严重炎症副作用的情况下进行全身的治疗.
通过β-glucuronidase催化激活来实现IMQ的瘤特异性释放.
控制的分娩促进了M1巨细胞的两极分化,T细胞的激活,并增加了IgG水平,仅在恶性组织中.

结论:

向瘤微环境特异性使小分子免疫调节剂的选择性输送成为可能.
这种方法为开发更安全,更有效的癌症免疫疗法提供了一个有希望的策略.

更多相关视频

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...